FDA approves luspaterecpt-aamt for anemia
from Drug Topics
The Food and Drug Administration has approved luspaterecpt-aamt (Rebloyzl, Celgene) for the treatment of anemia in adult patients with beta thalassemia (a rare, inherited blood disorder caused by genetically defunct hemoglobin) who require regular RBC transfusions. Luspaterecpt-aamt is currently the first and only erythroid maturation agent approved by the FDA, according to Celgene’s official release, thus representing a new class of drug therapy for patients with anemia.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063